The reasons for understanding the age-related macular degeneration (AMD)
In Canada, as in other countries with high per capita income, the widespread availability of anti-HIV high-power combination therapies (commonly called ART - Antiretroviral Therapy in freely or translation HAART) has a huge reduction related deaths AIDS and opportunistic infections. In addition, the researchers hope that more and more users ANTIRETROVIRAL THERAPY live up to 80 years.
Therefore, in patients whose immune systems have been improved and stabilized thanks to Antiretroviral Therapy, the focus of attention, probably will eventually change for the prevention and treatment of conditions related to the aging process. A complication as this will ultimately achieve the eye in its most sensitive part, which is the spot, with a disease called related macular degeneration with age (AMD). Before we talk about AMD, we will initially provide some aspects that need a great deal of minimal understanding and then AMD HIV-positive people or AIDS patients with respect to the "eye fund" and the extreme need to seek, as soon as possible, the search for a good ophthalmologist, preferably in a specialized ophthalmology clinic.
On the eyes
Light enters the eye and is focused by the lens (lens) and is thus that lands on the retina. The retina of the eye is sensitive to light. It converts the light into electrical signals that are sent to the brain, which interprets and gives us the notion of all that this around us and perhaps (?) Our most important among all sense.
Near the center of the retina is a group of cells called the macula. This is the most sensitive part of the retina. The macula is required for clear vision of objects that are in our field of vision.
AMD is a relatively common condition that can occur in people who have 50 years and older (although it is more common among people with 65 years of life or more). In the case of AMD the macula degrades, resulting in changes in vision. There are two forms of macular degeneration, as follows:
- Dry AMD - macula cells slowly break down, resulting in blurred vision
- Wet AMD - extra blood vessels grow under the retina; These blood vessels tend to be weak and leaking fluids which ultimately result in damage to the macula
There are three stages of AMD as follows:
- The Home AMD - some small or medium yellow deposits (drusen calls) that are under the retina; visual loss is uncommon in early AMD.
- Intermediate AMD - large drusen are present and there is a degree of vision loss.
- AMD Late - large drusen are present and there is a degree of vision loss.
Not all people with late AMD will develop AMD.
However, since changes in vision may sometimes be sudden, it is important to make regular examinations of the eye, especially for people over 50 years.
Although no treatment can reverse Wet AMD, A professional eye care can help in screening for AMD and soften it with options of various treatments.
In case of processes AMD dry, Your doctor may recommend some specific supplements that have been found to minimize the effects of AMD in clinical trials.
Some risk factors for AMD can not be changed, such as the following:
- Genetic - people with close relatives (parents and siblings) who are or have undergone AMD processes.
- Racial - white people are at greater risk
With the help of a professional and counseling, the following risk factors can be changed:
- Cardiovascular diseases
- High pressure levels in antiretroviral therapy
- Chronic inflammation
- A diet without colorful fruits and vegetables
The next newsletter CATIE News will provide information on the diagnosis of AMD in HIV-positive patients.
By Sean R. Hosein
Note Editor. Although the text speak that "countries with the highest per capita income may obtain advances and superior control of the quality of life of PLWHA. This phenomenon, the control of viral load at undetectable levels, is widely loculated in Brazil and, for us, the idea of the great difficulty in obtaining an undetectable viral load is strange, since, in general, AIDS patients Of the House of AIDS) (recent history of the AIDS home), Where I treat myself, these levels are achieved between three and six months after the start of treatment! (...) I also note that this text, on the date of its publication, on Good Friday, April 3, 2015, may seem somewhat disagreeable from the scope of the site, and yet it will begin to make sense when I publish the next text, on Monday, April 6, 2015 the 12h15m.
This information was provided by CATIE (Canada Exchange of AIDS treatment information). For more information, contact CATIE, 1.800.263.1638 or via email at Catie. The credit must appear on any online publication, with a link back to the original.
The translation into Brazilian Portuguese can not be used without the prior written authorization of those responsible for the Seropositive Web Site, subjecting the offender to the possible implications of the laws covering intellectual property rights. Note that in general, I will hardly deny the use of the text itself, provided the credits are given. However, exact replication of the page, making use of the images that I am forced to buy to maintain some originality and not fall into the sameness, I will not authorize. If you want to get good quality photos for surprisingly low prices, click on this link, which opens in another tab and on another site. Thank you
Translation adaptation and revision of the original in Canadian English to Portuguese of Brazil (it does not exist Brazil with "z" and "BraZil" is in the idiomatic aberration created for persons that only God knows why they do this and which obscure intention they may have ...) of the original in Aging eyes and macular degeneration by Claudio Souza
- The Holz FG, Schmitz-Valckenberg S, Fleckenstein M. Recent developments in the treatment of age-related macular degeneration. Clinical research officer. 2014 Apr; 124 (4): 1430-8.
- Nussenblatt RB, Lee RW, chew E, et al. Immune responses in age-related macular degeneration and a possible long-term therapeutic strategy for prevention. American Journal of Ophthalmology. 2014 Jul; 158 (1): 5-11.
- Schramm CE, Clark SJ, Triebwasser MP, et al. Genetic variants of the complement system predisposing to age - related macular degeneration: a review. Molecular Immunology. 2014 Oct; 61 (2): 118-25.
- Aronow-ME, chew EY. Age-Related Eye Disease Study 2: perspectives and recommendations and unanswered questions. Ophthalmology Course Opinion. 2014 May; 25 (3): 186-90.
- Next in this dossier, there will be G, chewing EY, Ferris FL, et al. Prevalence of anti-retinal autoantibodies at different stages of age-related macular degeneration. The BMC Oftalmologia.2014 Dec 8; 14: 154.
- Chew EY, Clemons TE Agrón And, et al. Ten years of follow-related macular degeneration age related eye disease age stu.